Bieniasz is being honored for his work on the life cycle of retroviruses and their interactions with host proteins. With his election, nearly half of Rockefeller faculty are NAS members.
The findings in mice may explain how addictive drugs hijack natural reward processing systems, creating the urge to use while throwing natural urges to eat and drink off-kilter.
Thomas Tuschl has devoted his career to making discoveries that bridge the gap between bench and business—and have resulted in entirely new classes of drugs.
The author of There Are Places in the World Where Rules Are Less Important Than Kindness was presented with Rockefeller’s prestigious science writing award on April 9.
SNFiRU, which aims to better understand the agents that cause infectious disease and to lower barriers to treatment and prevention globally, launched numerous initiatives in its inaugural year.
Retinoic acid, the active state of Vitamin A, appears to regulate how stem cells enter and exit a transient state central to their role in wound repair.
uLIPSTIC, an updated method for directly observing physical interactions between cells, could allow scientists to one day map every possible cell interaction.
A novel platform allows researchers to directly target enzymes implicated in infectious diseases, several genetic disorders, and some cancers for the first time.
Mojsov's research into hormonal triggers for insulin production led to groundbreaking treatments for diabetes and obesity. She will be presented with the award on April 17.
The end replication problem dictates that telomeres shrink unless telomerase intervenes. But the problem is actually twice as complicated, with telomerase providing only part of the solution.
The absence of a single immune cell receptor has been linked to both fewer defenses against mycobacterial infections, such as TB, and damaging buildup of sticky residue in the lungs.
A class of ineffective immune cells may be driving Alzheimer’s disease, a finding that could both explain why APOE4 gene increases the risk of the disease and why a new drug can impact it.
